Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Enteris BioPharma’s Partner Doses First Patient With New Drug

By Enteris BioPharma, Inc. | March 2, 2018

Enteris BioPharma, Inc, a biotechnology company, announced that Cara Therapeutics has successfully initiated a Phase One clinical trial of its oral formulation of CR845/difelikefalin (Korsuva) in patients with chronic liver disease (CLD). The oral tablet formulation of Korsuva was engineered using Enteris’ proprietary oral peptide and small molecule delivery technology, Peptelligence.

The oral Korsuva Phase One initiation marks the fourth clinical program involving an oral formulation of Cara Therapeutics’ CR845. Oral CR845 is also the subject of a Phase Two program in chronic pain, a Phase One program in hemodialysis chronic kidney disease, and a Phase One program in non-hemodialysis chronic kidney disease patients.

The oral tablet formulation of CR845 was developed in accordance with a manufacturing and clinical supply agreement between Cara Therapeutics and Enteris whereby Enteris utilized its Peptelligence technology to enable the active ingredient, which was initially formulated for I.V. or injection administration, to be delivered orally.

Under the terms of the “Feasibility-to-Licensing” program, Enteris will continue to manufacture the oral tablet formulation of CR845 for current and potential future studies through Phase Two that Cara Therapeutics elects to pursue. 

“Extending Oral CR845 into the treatment of pruritus related to liver disease further illustrates Peptelligence as a technology-of-choice for enabling the transition of peptide therapeutics from injection to oral delivery,” said Joel Tune, chief executive officer and executive chairman of Enteris BioPharma.

The FDA has conditionally accepted Korsuva as the trade name of difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

(Source: Enteris BioPharma, Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE